ALK+ ALCL is the most treatable form of systemic ALCL, with an overall response rate of up to 90%, a relapse-free survival of about 60%, and a 5-year overall survival of about 70%15. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.